Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-05-01
|
| Series: | Journal of Virus Eradication |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020311298 |
| _version_ | 1831752706516058112 |
|---|---|
| author | Macaya Douoguih Neil Goldstein Stephan Bart Kerstin Luhn Wilbert Van Duijnhoven Carla Truyers Benoit Callendret |
| author_facet | Macaya Douoguih Neil Goldstein Stephan Bart Kerstin Luhn Wilbert Van Duijnhoven Carla Truyers Benoit Callendret |
| author_sort | Macaya Douoguih |
| collection | DOAJ |
| first_indexed | 2024-12-21T23:07:54Z |
| format | Article |
| id | doaj.art-581e2c4872c24a7b87f14680f14b4462 |
| institution | Directory Open Access Journal |
| issn | 2055-6640 |
| language | English |
| last_indexed | 2024-12-21T23:07:54Z |
| publishDate | 2016-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj.art-581e2c4872c24a7b87f14680f14b44622022-12-21T18:47:07ZengElsevierJournal of Virus Eradication2055-66402016-05-0121011Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adultsMacaya Douoguih0Neil Goldstein1Stephan Bart2Kerstin Luhn3Wilbert Van Duijnhoven4Carla Truyers5Benoit Callendret6Janssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The NetherlandsJanssen Infectious Diseases and Vaccines, Leiden, The Netherlandshttp://www.sciencedirect.com/science/article/pii/S2055664020311298 |
| spellingShingle | Macaya Douoguih Neil Goldstein Stephan Bart Kerstin Luhn Wilbert Van Duijnhoven Carla Truyers Benoit Callendret Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults Journal of Virus Eradication |
| title | Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults |
| title_full | Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults |
| title_fullStr | Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults |
| title_full_unstemmed | Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults |
| title_short | Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults |
| title_sort | safety and immunogenicity of heterologous ad26 zebov and mva bn r filo prime boost ebola vaccines 6 month follow up of a phase i randomized trial in healthy adults |
| url | http://www.sciencedirect.com/science/article/pii/S2055664020311298 |
| work_keys_str_mv | AT macayadouoguih safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT neilgoldstein safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT stephanbart safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT kerstinluhn safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT wilbertvanduijnhoven safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT carlatruyers safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults AT benoitcallendret safetyandimmunogenicityofheterologousad26zebovandmvabnfiloprimeboostebolavaccines6monthfollowupofaphaseirandomizedtrialinhealthyadults |